Scientific article
Open access

Etat des connaissances en 2018 sur les anticorps anti-PCSK9

Other titleCurrent update on PCKS9 inhibitors
Published inRevue médicale suisse, vol. 14, no. 596, p. 482-486
Publication date2018-02-28

PCSK9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (mAb) are new therapeutic agents to lower efficiently LDL-cholesterol levels. New data from large clinical trials suggest that the addition of PCSK9 mAb to statins can reduce the incidence of major adverse cardiovascular events in very high risk patients. Alirocumab and evolocumab are two agents available in Switzerland with specific limitations for reimbursement. PCSK9 mAb should be considered in patients with clinical atherosclerotic cardiovascular disease (ASCVD), as well as in patients with familial hypercholesterolemia without ASCVD who have substantially high LDL-cholesterol levels despite the use of statin at maximally tolerated dose with or without ezetimibe, or intolerance to appropriate doses of several statins.

  • Antibodies, Monoclonal / therapeutic use
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / drug therapy
  • PCSK9 Inhibitors
  • Proprotein Convertase 9
  • Switzerland
Citation (ISO format)
GENCER, Baris et al. Etat des connaissances en 2018 sur les anticorps anti-PCSK9. In: Revue médicale suisse, 2018, vol. 14, n° 596, p. 482–486. doi: 10.53738/REVMED.2018.14.596.0482
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation04/02/2022 5:22:00 AM
First validation04/02/2022 5:22:00 AM
Update time03/16/2023 8:55:23 AM
Status update03/16/2023 8:55:23 AM
Last indexation08/31/2023 9:55:09 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack